Neuberger Berman Group
CHRS icon

Neuberger Berman Group’s Coherus Oncology CHRS Stock Holding History

Neuberger Berman Group’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.1K Sell
14,388
-287
-2% -$469 ﹤0.01% 2322
2026
Q1 		$24.8K Buy
14,675
+1,724
+13% +$3.06K ﹤0.01% 2140
2025
Q4 		$18.4K Sell
12,951
-4,157
-24% -$6.06K ﹤0.01% 2096
2025
Q3 		$28.1K Sell
17,108
-5,263
-24% -$5.85K ﹤0.01% 2015
2025
Q2 		$16.4K Buy
22,371
+4,341
+24% +$3.75K ﹤0.01% 2032
2025
Q1 		$14.6K Buy
+18,030
New +$20.8K ﹤0.01% 1951

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Neuberger Berman Group's CHRS Position: Q2 2026 in Review

Neuberger Berman Group reduced its Coherus Oncology (CHRS) stake by 2% in Q2 2026, selling an estimated $469 and leaving 14,388 shares worth $20.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2322.

Neuberger Berman Group first reported a position in CHRS in Q1 2025 and has held it in 6 quarters since. The position peaked at $28.1K in Q3 2025. 147 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • Neuberger Berman Group held 14,388 shares of Coherus Oncology worth $20.1K as of Q2 2026.
  • Neuberger Berman Group sold 287 Coherus Oncology shares in Q2 2026, an estimated $469.
  • Coherus Oncology made up ﹤0.01% of Neuberger Berman Group's portfolio in Q2 2026, its #2322 holding.
  • Neuberger Berman Group first reported a position in Coherus Oncology in Q1 2025 and has held it in 6 quarters since.
  • Neuberger Berman Group's Coherus Oncology position peaked at $28.1K in Q3 2025.
  • 147 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Neuberger Berman Group's 13F filing for Q2 2026, filed 13 Aug 2026.